RxDoctor Payments Data

Abida Hasan, DO

Rheumatology · Katy, TXNPI 1346747086

Payments from drug & device makers

$2,369in general payments, 2019–2025

Across 87 payments — averaging $27.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$416
  • AbbVie$340
  • AstraZeneca$286
  • Novartis$238
  • Mallinckrodt Hospital Products Inc.$235
  • Edwards Lifesciences$199
  • plus $656 from 10 others

What the payments were for

  • Food & beverage$2,35099%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,369 in reported general payments places this provider in the 35th percentile of 512 rheumatology providers in Texas.

See all rheumatology providers in Texas

Medicare billing

Part B allowed, 2024
$18,796
Medicare patients
56
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept42$296,736
Humira PenAdalimumab33$229,155
HumiraAdalimumab25$208,747
Orencia ClickjectAbatacept13$70,160
Mycophenolate Mofetil43$7,102
Hydroxychloroquine Sulfate180$4,657
MethotrexateMethotrexate Sodium174$3,466
Leflunomide36$2,458
Sulfasalazine40$909
Tacrolimus12$855
Prednisone89$704
Gabapentin13$650
Azathioprine22$630
Diclofenac Sodium12$295
Pantoprazole Sodium18$186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira$340$208,74725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 512 rheumatology providers in Texas.

Other rheumatology in Katy

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →